KAHR
's headquarters is in Jerusalem, Jerusalem District. Yaron Pereg is the CEO of KAHR. KAHR has raised a total of $51.5M in funding. KAHR has 1 followers on Owler. KAHR has an estimated revenue of <$1M and an estimate of less <10 employees.KAHR
's headquarters is in Jerusalem, Jerusalem District. Yaron Pereg is the CEO of KAHR. KAHR has raised a total of $51.5M in funding. KAHR has 1 followers on Owler. KAHR has an estimated revenue of <$1M and an estimate of less <10 employees.
News
Jan 09, 2026
Pulse2.0
KAHR: KAHR Bio: $22 Million Raised And Phase 2 Topline Data For DSP107 Combo In MSS Colorectal Cancer
Jun 02, 2025
PR Newswire
Press Release: KAHR : KAHR Bio Announces Positive Phase 2 Results of DSP107 in Combination with anti-PD-L1 in Colorectal Cancer
May 31, 2023
StreetInsider
Press Release: KAHR : KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors
Nov 17, 2022
BioSpace
KAHR: Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma
Mar 15, 2022
PR Newswire
Press Release: KAHR : KAHR Announces Publication of Preclinical Data Indicating Monotherapy and Combination Treatment Potential of its Investigational Anti-CD47 Fusion Protein
Nov 23, 2021
GlobeNewswire
Press Release: KAHR : KAHR to Host Key Opinion Leader Webinar on the Potential of CD47 Therapeutics for the Treatment of Solid Tumor and Hematologic Malignancies
Sep 02, 2021
StreetInsider
Press Release: KAHR : KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers
Jun 21, 2021
NoCamels
KAHR: Cancer Immunotherapy Company Kahr Medical Raises $46.5M
Jun 17, 2021
Jewish Business News
KAHR: Israel's KAHR Cancer Treatment Medtech Startup Raises $46.5 Million
Jun 16, 2021
CTech
KAHR: KAHR announced $46.5 million funding round to advance its immunotherapeutic pipeline